Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan P, Kier M, Laughlin AI, Kothari S, Giles JR, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney D, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn A, Blank C, Weber J, Mitchell TC, Farwell MD, Herati R, Huang AC. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells. , Cancer Cell, 42(9): 2024,1582-1597
Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Matthew D, Chen Q, Khan O, Wu JE, ALcade V, Flowers AJ, McClain S, Baxter AE, Kurachi M, Shi J, Huang AC, Giles JR, Sharpe AH, Vignali, DAA, Wherry EJ. LAB-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK expression and cytotoxicity. , Cell, 187(16): 2024,4336-4354
Mathew D, Maramareis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Carpenter EL, Langer CJ, Wherry EJ, Minn AJ. Combined JAK Inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. , Science, 384(6702): 2024
Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD. FDG PET/CT Imaging 1 Week after a Singel Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma , Clin Cancer Res , 30(9): 2024
Beltra JC, Abdel-Hakeem MS, Manne S, Zhang Z, Huang H, Kurachi M, Su L, Picton L, Ngiow SF, Muroyama Y, Casella V, Huang YJ, Giles JR, Mathew D, Belman J, Klapholz M, Decaluwe H, Huang AC, Berger SL, Garcia KC, Wherry EJ. Stat5 opposes the transcription factor Tox and rewires exhausted CD3(+) T cells toward durable effector-like states during chronic antigen exposure. , Immunity, 56(12): 2023,2699-2718
Kevin L Ma, Cimarron E Sharon, Andrew Kossenkov, Lynn M Schuchter, Ravi K Amaravadi, Tara C Mitchell, John T Miura, Xiaowei Xu, Alexander C Huang, Giorgos C Karakousis Immune microenvironment in sentinel lymph nodes of high-risk clinical stage IIB/C melanoma , Society for Melanoma Research (SMR) Congress, Philadelphia, PA.: 2023
Guanning Wang1, Daniel Yoon2, Justin Kim1, Aaron Nickie1, Stella Park1, Ajeya Nandi1, Patrick Yan1, Mary Carberry1, Lydia Giles1, Khushboo Patel1, Ravi K. Amaravadi1, Lynn M. Schuchter1, Giorgos C. Karakousis1, Xiaowei Xu1, Tara. C. Mitchell, Alexander C. Huang Antigen-specific profiling for neoadjuvant anti-PD-1 therapy in melanoma , Society for Melanoma Research (SMR Congress), Philadelphia, PA.: 2023
Painter MM, Johnston TS, Lundgreen KA, Santos JJS, Qin JS, Goel RR, Apostolidis SA, Mathew D, Fulmer B, Williams JC, McKeague ML, Pattekar A, Goode A, Nasta S, Baxter AE, Giles JR, Skelly AN, Felley LE, McLaughlin M, Weaver J, Kuthuru O, Dougherty J, Adamski S, Long S, Kee M, Clendenin C, da Silva Antunes R, Grifoni A, Weiskopf D, Sette A, Huang AC, Rader DJ, Hensley SE, Bates P, Greenplate AR, Wherry EJ. Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV2 breakthrough infection. , Nat Immunol, 24(10): 2023,1711-1724
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma. , Ann Oncol, 34 (9): 2023,806-812
Sharon CE, Tortorello GN, MA KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Muira JT, Karakousis GC, Mitchell TC Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneus melanoma. , Ann Oncol, 34(9): 2023,806-812
